4basebio (LON:4BB – Get Free Report) announced its quarterly earnings results on Monday. The company reported GBX (0.57) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
4basebio Stock Performance
Shares of LON 4BB traded down GBX 2.70 during trading hours on Tuesday, reaching GBX 559.80. The stock had a trading volume of 261 shares, compared to its average volume of 1,353. The firm has a 50-day moving average of GBX 511.05 and a 200-day moving average of GBX 510.01. The firm has a market cap of £86.69 million, a price-to-earnings ratio of -5.14 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. 4basebio has a fifty-two week low of GBX 420 and a fifty-two week high of GBX 820.
Analyst Ratings Changes
Separately, Royal Bank Of Canada decreased their target price on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating for the company in a research note on Monday, June 15th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of GBX 1,400.
4basebio Company Profile
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Recommended Stories
- Five stocks we like better than 4basebio
- Tesla’s Semi Is Finally Here—But Will It Move the Stock?
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
- Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
- NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
